207 related articles for article (PubMed ID: 16323973)
21. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
Moody AP; al-Khaffaf HS; Lehert P; Harris PL; Charlesworth D
J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S44-7. PubMed ID: 7517477
[TBL] [Abstract][Full Text] [Related]
22. Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication.
Rosas G; Cerdeyra C; Lucas MA; Parano JR; Villa JJ
Angiology; 1981 May; 32(5):291-7. PubMed ID: 7235299
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of the efficacy and tolerance of naftidrofuryl in patients presenting with exertional angina. Multicenter double-blind versus placebo study].
Hirsch JL; Bensoussan JJ; Mosnier M; Lehert P
Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):137-45. PubMed ID: 12555338
[TBL] [Abstract][Full Text] [Related]
24. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
[TBL] [Abstract][Full Text] [Related]
25. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis.
Girolami B; Bernardi E; Prins MH; Ten Cate JW; Hettiarachchi R; Prandoni P; Girolami A; Büller HR
Arch Intern Med; 1999 Feb; 159(4):337-45. PubMed ID: 10030306
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
Meng Y; Squires H; Stevens JW; Simpson E; Harnan S; Thomas S; Michaels J; Stansby G; O'Donnell ME
Angiology; 2014 Mar; 65(3):190-7. PubMed ID: 23378195
[TBL] [Abstract][Full Text] [Related]
27. Intravenous naftidrofuryl for critical limb ischaemia.
Smith FB; Bradbury AW; Fowkes FG
Cochrane Database Syst Rev; 2000; (2):CD002070. PubMed ID: 10796677
[TBL] [Abstract][Full Text] [Related]
28. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Roset PN
Br J Surg; 2013 Dec; 100(13):1838. PubMed ID: 24227374
[No Abstract] [Full Text] [Related]
29. Effects of naftidrofuryl in patients with intermittent claudication.
Karnik R; Valentin A; Stöllberger C; Slany J
Angiology; 1988 Mar; 39(3 Pt 1):234-40. PubMed ID: 3281516
[TBL] [Abstract][Full Text] [Related]
30. The effect of naftidrofuryl on transcutaneous oxygen tension during a treadmill test in patients with peripheral arterial occlusive disease.
Mouren X; Caillard P; Bensoussan JJ; Massonneau M; Gamand S; Stevens WH
Vasc Med; 1998; 3(1):9-14. PubMed ID: 9666526
[TBL] [Abstract][Full Text] [Related]
31. [Clinical effectiveness of naftidrofuryl in intermittent claudication].
Kriessmann A; Neiss A
Vasa Suppl; 1988; 24():27-32. PubMed ID: 3062823
[No Abstract] [Full Text] [Related]
32. Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
Br J Surg; 2013 Dec; 100(13):1838-9. PubMed ID: 24227373
[No Abstract] [Full Text] [Related]
33. The effect of naftidrofuryl on intermittent claudication: a meta-analysis.
Lehert P; Riphagen FE; Gamand S
J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S81-6. PubMed ID: 1369727
[TBL] [Abstract][Full Text] [Related]
34. Silence of the limbs pharmacological symptomatic treatment of intermittent claudication.
De Backer T; Vander Stichele R; De Buyzere M; De Backer G; Van Bortel L
Curr Vasc Pharmacol; 2010 May; 8(3):383-7. PubMed ID: 19485897
[TBL] [Abstract][Full Text] [Related]
35. Naftidrofuryl for intermittent claudication: a double-blind controlled trial.
Ruckley CV; Callam MJ; Ferrington CM; Prescott RJ
Br Med J; 1978 Mar; 1(6113):622. PubMed ID: 343869
[No Abstract] [Full Text] [Related]
36. [Double-blind randomized comparative study of nicergoline naftidrofuryl on the quality of life in chronic obliterative arteriopathy of lower limbs with intermittent claudication].
Meilhac B; Montestruc F; Aubin F; Djian F; Rouffy J
Therapie; 1997; 52(3):179-86. PubMed ID: 9366101
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological approaches to the treatment of intermittent claudication.
Bevan EG; Waller PC; Ramsay LE
Drugs Aging; 1992; 2(2):125-36. PubMed ID: 1596595
[TBL] [Abstract][Full Text] [Related]
38. Naftidrofuryl in intermittent claudication: a retrospective analysis.
Lehert P; Comte S; Gamand S; Brown TM
J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S48-52. PubMed ID: 7517478
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
Thompson PD; Zimet R; Forbes WP; Zhang P
Am J Cardiol; 2002 Dec; 90(12):1314-9. PubMed ID: 12480040
[TBL] [Abstract][Full Text] [Related]
40. [Naftidrofuryl in the therapy of chronic arterial occlusive disease in the intermittent claudication stage].
Valentin A; Karnik R; Stöllberger C; Slany J
Vasa Suppl; 1987; 20():361-4. PubMed ID: 3321493
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
